Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a ...
Erich Rajkovic Erich Rajkovic - new Eleva CBO Freiburg im Breisgau, Germany – January 8, 2026 – Eleva, a pioneer in discovering and developing previously inaccessible biologics, today announced the ...
Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...
The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...
Floquet control uses time-periodic drives to engineer quantum systems, creating dynamic changes in material properties ...
Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluationCompelling anti-inflammatory activity of G1090N was ...
Abstract: This work presented a fractional-N digital PLL that leveraged pseudo-random phase modulation and demodulation technique to mitigate fractional spurs. By decoupling the periodicity of control ...
Corcept Therapeutics (CORT) leverages Korlym’s commercial success in hypercortisolism, generating $559.3M in nine-month 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback